PMC:7346000 / 213-714 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":43,"end":51},"obj":"Species"},{"id":"37","span":{"begin":65,"end":88},"obj":"Disease"},{"id":"38","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"39","span":{"begin":127,"end":150},"obj":"Disease"},{"id":"40","span":{"begin":251,"end":259},"obj":"Disease"},{"id":"41","span":{"begin":276,"end":328},"obj":"Disease"},{"id":"42","span":{"begin":370,"end":393},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D055732"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:C000657245"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D055732"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"MESH:C000657245"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D008171"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D055732"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunit"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T9","span":{"begin":75,"end":88},"obj":"Disease"},{"id":"T10","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"T11","span":{"begin":137,"end":150},"obj":"Disease"},{"id":"T12","span":{"begin":152,"end":156},"obj":"Disease"},{"id":"T13","span":{"begin":251,"end":259},"obj":"Disease"},{"id":"T14","span":{"begin":308,"end":328},"obj":"Disease"},{"id":"T15","span":{"begin":380,"end":393},"obj":"Disease"}],"attributes":[{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"d as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunit"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":95,"end":97},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T3","span":{"begin":286,"end":296},"obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"T4","span":{"begin":470,"end":480},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"d as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunit"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":484,"end":493},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"d as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunit"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":185,"end":394},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"d as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunit"}